Physician

Aijaz A. Gundroo, MD

According to 2025 Medicare claims, Aijaz Gundroo, MD (NPI: 1881660900) practices nephrology in the Columbus, OH market, with the plurality of this provider's patient population coming from Franklin, OH. This provider's primary affiliated billing organization is OSU INTERNAL MEDICINE, LLC (NPI: 1740231448; TIN: 311369596) and primary practice location at 43210-1240. Gundroo is affiliated with the CVS ACO (ACO ID: A5407), participating under the MSSP model.

Gundroo's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 254 traditional Medicare patients, billed 727 HCPCS/CPT codes, and received $56,969 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 414 prescription claims across 76 beneficiaries totaling $66,743 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 257 claims. Open Payments data shows 2 records totaling $57. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $82,114 and ending at $56,969. Concurrently, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $139,122 to $66,743. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	223	830	$82,114
2016	221	880	$73,733
2017	177	643	$49,747
2018	198	808	$53,628
2019	251	650	$47,862
2020	286	641	$48,842
2021	327	1,049	$88,987
2022	250	685	$55,165
2023	258	773	$63,651
2024	254	727	$56,969

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	98	671	$139,122
2016	84	512	$166,436
2017	89	622	$104,493
2018	84	325	$47,955
2019	30	138	$19,447
2020	75	246	$17,688
2021	65	276	$28,616
2022	62	356	$32,224
2023	75	307	$31,658
2024	76	414	$66,743

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	14	94	$7,204
2016	59	188	$17,739
2017	N/R	41	$1,894
2018	N/R	92	$3,764
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	205	$7,182
2023	11	243	$4,529
2024	N/R	257	$5,419

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	77	90	$97
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	102	282	$90
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	66	104	$60
90935	Hemodialysis procedure with physician evaluation	72	149	$53
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	27	37	$46

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	15	510	$32,662
Jardiance	Empagliflozin	12	360	$7,212
Retacrit	Epoetin Alfa-Epbx	15	420	$6,651
Sevelamer Carbonate	Sevelamer Carbonate	14	600	$1,433
Potassium Citrate Er	Potassium Citrate	12	1,005	$1,279

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	45	$1,449
J7502	Cyclosporine, oral, 100 mg	N	N/R	11	$1,236
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	76	$1,191
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	47	$847
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	60	$687

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$57	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aijaz A. Gundroo, MD?

Tedicare shows public-source Medicare data for Aijaz A. Gundroo, MD (NPI 1881660900), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aijaz A. Gundroo, MD have ACO affiliation data?

Aijaz A. Gundroo, MD is shown with ACO affiliation data for CVS ACO (MSSP, ACO ID A5407).

What billing organization is linked to Aijaz A. Gundroo, MD?

Aijaz A. Gundroo, MD is linked to OSU INTERNAL MEDICINE, LLC (billing NPI 1740231448) in the available physician profile data.

Does Aijaz A. Gundroo, MD have Open Payments data?

Aijaz A. Gundroo, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.